A novel multi-stage enrichment workflow and comprehensive characterization for HEK293F-derived extracellular vesicles.

Autor: Vo N; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Tran C; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Tran NHB; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Nguyen NT; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Nguyen T; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Ho DTK; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Nguyen DDN; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Pham T; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Nguyen TA; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Phan HTN; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Nguyen HN; Medical Genetics Institute, Ho Chi Minh City, Vietnam., Tu LN; Medical Genetics Institute, Ho Chi Minh City, Vietnam.
Jazyk: angličtina
Zdroj: Journal of extracellular vesicles [J Extracell Vesicles] 2024 May; Vol. 13 (5), pp. e12454.
DOI: 10.1002/jev2.12454
Abstrakt: Extracellular vesicles (EVs) are emerging as a promising drug delivery vehicle as they are biocompatible and capable of targeted delivery. However, clinical translation of EVs remains challenging due to the lack of standardized and scalable manufacturing protocols to consistently isolate small EVs (sEVs) with both high yield and high purity. The heterogenous nature of sEVs leading to unknown composition of biocargos causes further pushback due to safety concerns. In order to address these issues, we developed a robust quality-controlled multi-stage process to produce and isolate sEVs from human embryonic kidney HEK293F cells. We then compared different 2-step and 3-step workflows for eliminating protein impurities and cell-free nucleic acids to meet acceptable limits of regulatory authorities. Our results showed that sEV production was maximized when HEK293F cells were grown at high-density stationary phase in semi-continuous culture. The novel 3-step workflow combining tangential flow filtration, sucrose-cushion ultracentrifugation and bind-elute size-exclusion chromatography outperformed other methods in sEV purity while still preserved high yield and particle integrity. The purified HEK293F-derived sEVs were thoroughly characterized for identity including sub-population analysis, content profiling including proteomics and miRNA sequencing, and demonstrated excellent preclinical safety profile in both in-vitro and in-vivo testing. Our rigorous enrichment workflow and comprehensive characterization will help advance the development of EVs, particularly HEK293F-derived sEVs, to be safe and reliable drug carriers for therapeutic applications.
(© 2024 The Author(s). Journal of Extracellular Vesicles published by Wiley Periodicals LLC on behalf of International Society for Extracellular Vesicles.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje